{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:50:21Z","timestamp":1791478221093,"version":"4.3.4"},"reference-count":41,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Tianjin Science and Technology Bureau","award":["24ZYJDSS00150"],"award-info":[{"award-number":["24ZYJDSS00150"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: The combined diphtheria\u2013tetanus\u2013acellular pertussis (three-component), Haemophilus influenzae type b (Hib, conjugate), and ACYW135 meningococcal (conjugate) vaccine (DTaP-Hib-MCV4) offers a promising alternative to single-component vaccines, potentially simplifying immunization schedules and improving vaccination coverage. Methods: We evaluated the safety, immunogenicity, and protective efficacy of DTaP-Hib-MCV4 in animal models. Acute and long-term toxicity studies were conducted in Sprague-Dawley (SD) rats with equal numbers of male and female animals. Immunogenicity was assessed in female NIH mice and SD rats using a three-dose regimen at 14-day intervals. Orbital blood was collected 14 days post-immunization to measure IgG titers against pertussis, diphtheria, tetanus, Hib, and meningococcal antigens. The protective efficacy was determined using potency tests for the pertussis, diphtheria, and tetanus components; passive protection studies for Hib; and serum bactericidal antibody (SBA) titers against A\/C\/Y\/W135 meningococcal serogroups. Results: Acute and repeated-dose toxicity studies in SD rats showed no signs of abnormal toxicity or irritation at either high (three doses\/rat) or low (one dose\/rat) doses levels. The no-observed-adverse-effect level (NOAEL) for DTaP-Hib-MCV4 was established at three doses\/rat after 8 weeks of repeated intramuscular administration and a 4-week recovery period. Specific IgG antibodies against all the vaccine components were detected in animal sera at both one and three doses\/rat, with no evidence of immunotoxicity. Following two-dose primary immunization in murine models, the combined vaccine elicited robust antigen-specific antibody responses, with geometric mean titers (GMTs) as follows: 1,280,000 for pertussis toxin (PT); 761,093 for filamentous hemagglutinin (FHA); 1,159,326 for pertactin (PRN); 1,659,955 for diphtheria toxoid (DT); 1,522,185 for tetanus toxoid (TT); 99 for Haemophilus influenzae type b (Hib); and 25,600, 33,199, 8300, and 9051 for serogroups A, C, Y, and W135 of Neisseria meningitidis, respectively. In the rat models, three-dose primary immunization also elicited robust antigen-specific antibody responses. Protection studies demonstrated efficacy against pertussis, tetanus toxin, and diphtheria toxin challenges. In the Hib challenge study, none of the 10 animals given anti-DTaP-Hib-MCV4 antiserum developed bacteremia after the live Hib challenge (vs. 5814\/0.1 mL in the negative control, p &lt; 0.001). In addition, the SBA titers against meningococcal serogroups exceeded the protective threshold (\u22651:8) in 92.2% of the immunized mice and 100% of the immunized rats. Crucially, the combined vaccine induced potent immune responses and protective efficacy, with antibody levels and protection against each component antigen comparable to or greater than those of the individual components: DTaP, Hib, and MCV4. Conclusions: These findings demonstrate that the DTaP-Hib-MCV4 combined vaccine is both safe and immunogenic, supporting its potential as a viable alternative to individual vaccines. This combined vaccine may streamline immunization programs and enhance vaccination coverage.<\/jats:p>","DOI":"10.3390\/vaccines13070724","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T04:07:17Z","timestamp":1751515637000},"page":"724","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["An Evaluation of the Safety, Immunogenicity, and Protective Efficacy of a Combined Diphtheria\u2013Tetanus\u2013Acellular Pertussis, Haemophilus influenzae Type b, and ACYW135 Meningococcal Conjugate Vaccine in Murine and Rat Models"],"prefix":"10.3390","volume":"13","author":[{"given":"Xiuwen","family":"Sui","sequence":"first","affiliation":[{"name":"CanSino Biologics Inc., Tianjin 300457, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5216-6537","authenticated-orcid":false,"given":"Zhujun","family":"Shao","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9642-6781","authenticated-orcid":false,"given":"Yuanyuan","family":"Ji","sequence":"additional","affiliation":[{"name":"CanSino Biologics Inc., Tianjin 300457, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairui","family":"Wang","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfu","family":"Xu","sequence":"additional","affiliation":[{"name":"CanSino Biologics Inc., Tianjin 300457, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bochao","family":"Wei","sequence":"additional","affiliation":[{"name":"CanSino Biologics Inc., Tianjin 300457, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuojun","family":"Duan","sequence":"additional","affiliation":[{"name":"CanSino Biologics Inc., Tianjin 300457, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Wang","sequence":"additional","affiliation":[{"name":"CanSino Biologics Inc., Tianjin 300457, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[{"name":"CanSino Biologics Inc., Tianjin 300457, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Zhao","sequence":"additional","affiliation":[{"name":"CanSino Biologics Inc., Tianjin 300457, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4197-0065","authenticated-orcid":false,"given":"Tao","family":"Zhu","sequence":"additional","affiliation":[{"name":"CanSino Biologics Inc., Tianjin 300457, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2160158","DOI":"10.1080\/21645515.2022.2160158","article-title":"Safety and immunogenicity of a combined DTacP-sIPV-Hib vaccine in animal models","volume":"18","author":"Zhang","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2372884","DOI":"10.1080\/21645515.2024.2372884","article-title":"Adverse events following immunization of co- and separate administration of DTaP-IPV\/Hib vaccines: A real-world comparative study","volume":"20","author":"Zhu","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1080\/21645515.2015.1044180","article-title":"The value of childhood combination vaccines: From beliefs to evidence","volume":"11","author":"Maman","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/INF.0b013e31805d7f17","article-title":"Use of combination vaccines is associated with improved coverage rates","volume":"26","author":"Marshall","year":"2007","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_5","unstructured":"World Health Organization (2014). DT-Based Combined Vaccines, World Health Organization."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3346\/jkms.2016.31.9.1383","article-title":"The Immunogenicity and Safety of a Combined DTaP-IPV\/\/Hib Vaccine Compared with Individual DTaP-IPV and Hib (PRP~T) Vaccines: A Randomized Clinical Trial in South Korean Infants","volume":"31","author":"Kang","year":"2016","journal-title":"J. Korean Med. Sci."},{"key":"ref_7","first-page":"252","article-title":"Disease burden and vaccine immunization status of epidemic cerebrospinal meningitis in infants","volume":"26","author":"Lin","year":"2025","journal-title":"Chin. Prev. Med."},{"key":"ref_8","first-page":"724","article-title":"Etiology and epidemiological analysis on the first ST\u20431655 complex serogroup Y Neisseria meningitidis isolated from patient in Shantou","volume":"22","author":"Huang","year":"2022","journal-title":"J. Trop. Med."},{"key":"ref_9","first-page":"73","article-title":"Investigation and Analysis of the First Case of Group Y Meningococcal Meningitis in Maoming City in 2020","volume":"30","author":"Mo","year":"2024","journal-title":"Strait J. Prev. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s11427-023-2378-x","article-title":"Multi-valent mRNA vaccines against monkeypox enveloped or mature viron surface antigens demonstrate robust immune response and neutralizing activity","volume":"66","author":"Zhang","year":"2023","journal-title":"Sci. China Life Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(99)04377-9","article-title":"Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis","volume":"354","author":"Eskola","year":"1999","journal-title":"Lancet"},{"key":"ref_12","first-page":"55","article-title":"Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign","volume":"6","author":"Trotter","year":"2003","journal-title":"Commun. Dis. Public Health"},{"key":"ref_13","first-page":"S694","article-title":"Combination vaccines","volume":"85","author":"Chokephaibulkit","year":"2002","journal-title":"J. Med. Assoc. Thail. = Chotmaihet Thangphaet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0300-483X(02)00055-0","article-title":"Non-clinical vaccine safety assessment","volume":"174","author":"Verdier","year":"2002","journal-title":"Toxicology"},{"key":"ref_15","unstructured":"World Health Organization (2003). WHO Guidelines on Non-Clinical Evaluation of Vaccines, Annex 1, World Health Organization. TRS No. 927."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1086\/426396","article-title":"Suppression and modulation of cellular and humoral immune responses to Haemophilus influenzae type B (Hib) conjugate vaccine in hib-diphtheria-tetanus toxoids-acellular pertussis combination vaccines: A study in a rat model","volume":"191","author":"Mawas","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_18","unstructured":"Chinese Pharmacopoeia Commission (2025). Group A and Group C Meningococcal Conjugate Vaccine. Chinese Pharmacopoeia 3.5.4 Potency Assay, Chinese Pharmacopoeia Commission."},{"key":"ref_19","unstructured":"Chinese Pharmacopoeia Commission (2025). Diphtheria, tetanus and pertussis vaccines. Chinese Pharmacopoeia 3.2.4 Potency Assay, Chinese Pharmacopoeia Commission."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1128\/iai.65.9.3701-3707.1997","article-title":"Outer membrane protein D15 is conserved among Haemophilus influenzae species and may represent a universal protective antigen against invasive disease","volume":"65","author":"Loosmore","year":"1997","journal-title":"Infect. Immun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/cdli.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2013serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nri3085","article-title":"Vaccines for the twenty-first century society","volume":"11","author":"Rappuoli","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"ref_24","unstructured":"Former State Food and Drug Administration of the People\u2019s Republic of China (2014). Technical Guidance for Single-Dose Toxicity Tests of Drugs (Announcement No. 4 of 2014), Former State Food and Drug Administration of the People\u2019s Republic of China."},{"key":"ref_25","unstructured":"Former State Food and Drug Administration of the People\u2019s Republic of China (2014). Technical Guidance for Repeated Dose Toxicity Studies of Drugs (Announcement No. 4 of 2014), Former State Food and Drug Administration of the People\u2019s Republic of China."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hogenesch, H. (2012). Mechanism of immunopotentiation and safety of aluminum adjuvants. Front. Immunol., 3.","DOI":"10.3389\/fimmu.2012.00406"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1016\/j.vaccine.2013.05.107","article-title":"Kinetics of the inflammatory response following intramuscular injection of aluminum adjuvant","volume":"31","author":"Lu","year":"2013","journal-title":"Vaccine"},{"key":"ref_28","first-page":"149","article-title":"Safety of pentavalent DTaP-IPV\/Hib combination vaccine in post-marketing surveillance in Guangzhou, China, from 2011 to 2017","volume":"99","author":"Li","year":"2020","journal-title":"Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Chen, Q., Zhang, C., Ye, C., Zhu, J., Shen, J., Zhu, C., Yang, P., Liu, T., and Xu, Y. (2024). Surveillance for adverse events following immunization with DTaP-containing combination vaccines in Linping, China, 2019-2022. Front. Public Health, 12.","DOI":"10.3389\/fpubh.2024.1278513"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e28326","DOI":"10.1016\/j.heliyon.2024.e28326","article-title":"Assessment of the immune interference effects of multivalent vaccine for influenza epidemic strain in 2022-2023 and evaluation of its efficacy","volume":"10","author":"Ga","year":"2024","journal-title":"Heliyon"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Dom\u00ednguez, I., Abdeljawad, A., Lai, T.Y., Boza, M., McCroskery, S., Lemus, N., Slamanig, S., Singh, G., Warang, P., and Yellin, T. (2025). Mucosal multivalent NDV-based vaccine provides cross-reactive immune responses against SARS-CoV-2 variants in animal models. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1524477"},{"key":"ref_32","first-page":"195","article-title":"Meta-analysis of safety and immunogenicity of DTaP-IPV-Hib-HepB hexavaccine","volume":"2","author":"Liu","year":"2024","journal-title":"Chin. J. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Wang, X., Gao, N., Wen, J., Li, J., Ma, Y., Sun, M., Liang, J., and Shi, L. (2021). Immunogenicity of a Candidate DTacP-sIPV Combined Vaccine and Its Protection Efficacy against Pertussis in a Rhesus Macaque Model. Vaccines, 10.","DOI":"10.3390\/vaccines10010047"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1080\/21645515.2019.1593082","article-title":"A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines","volume":"15","author":"Findlow","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1128\/CVI.00154-07","article-title":"Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis\/Hib combination vaccines","volume":"14","author":"Goldblatt","year":"2007","journal-title":"Clin. Vaccine Immunol. CVI"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2295977","DOI":"10.1080\/21645515.2023.2295977","article-title":"The urban-poor vaccination: Challenges and strategies in low-and-middle income countries","volume":"20","author":"Zimba","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ma, J., Li, Z., Sun, Y., Liu, Z., Dang, Y., and Huang, Y. (2022). Improving Innovation and Access to Combination Vaccines for Childhood Immunization in China. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph192315557"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bcp.2013.08.006","article-title":"Animal models of human disease: Challenges in enabling translation","volume":"87","author":"McGonigle","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref_39","first-page":"1805","article-title":"Immunogenicity and immune persistence of adsorbed diphtheria, tetanus and acellular pertussis combined vaccine","volume":"26","author":"Zou","year":"2013","journal-title":"Chin. J. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1073\/pnas.1816401115","article-title":"Polysaccharide structure dictates mechanism of adaptive immune response to glycoconjugate vaccines","volume":"116","author":"Sun","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Fatima, M., and Hong, K.J. (2025). Innovations, Challenges, and Future Prospects for Combination Vaccines Against Human Infections. Vaccines, 13.","DOI":"10.3390\/vaccines13040335"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/7\/724\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:03:31Z","timestamp":1760033011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/7\/724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["vaccines13070724"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13070724","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]}}}